Bleeding Disorders Therapeutics Market by Type and Geography - Forecast and Analysis 2020-2024

Bleeding Disorders Therapeutics Market by Type and Geography - Forecast and Analysis 2020-2024

Global Bleeding Disorders Therapeutics Market: About this market

Technavio’s bleeding disorders therapeutics market analysis considers sales from types of bleeding disorders therapeutics such as Hemophilia A, Hemophilia B, Von Willebrand disease, and other disorders. Our report also provides a detailed analysis of the market in Asia, Europe, North America, and ROW. In 2019, the Hemophilia A segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing demand for therapeutics without human or animal proteins will play a significant role in the Hemophilia A segment to maintain its market position. Also, our global bleeding disorders therapeutics market report looks at factors such as rising initiatives to increase awareness, recent approvals, and regulatory incentives. However, high costs of treatment, difficulties associated with early treatment, and challenges related to diagnosis and management of bleeding disorders may hamper the growth of the bleeding disorders therapeutics industry over the forecast period.

Global Bleeding Disorders Therapeutics Market: Overview

Rising initiatives to increase awareness

The awareness campaigns aids in the early detection of bleeding disorders, aiding patients to start therapy in the initial stages of the disorder. Organizations such as the National Hemophilia Foundation, von Willebrand Education Network, and World Federation of Hemophilia support and are focused on raising both awareness and research funds for bleeding disorders. This increasing awareness will lead to the expansion of the global bleeding disorders therapeutics market at a CAGR of almost 7% during the forecast period.

The emergence of gene therapy

Gene therapy is one of the most advanced and extensively researched treatment methods to treat hemophilia and von Willebrand disease. This therapy delivers stable insertion and expression of a gene, whose absence is responsible for a particular bleeding disorder. Therefore, the emergence and approval of gene therapies are expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global bleeding disorders therapeutics market during the forecast period 2020-2024, click here.

Competitive Landscape

With the presence of a few significant players, the global bleeding disorders therapeutics market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading bleeding disorders therapeutics manufacturers, that include Baxter International Inc., Bayer AG, CSL Ltd., F. Hoffmann-La Roche Ltd., Grifols SA, Novo Nordisk AS, Octapharma AG, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd.

Also, the bleeding disorders therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.


  • Executive summary
  • Scope of the report
    • Preface
      • Table Product overview
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global pharmaceuticals market
      • Table Segments of global pharmaceuticals market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2019
      • Table Market size 2019
    • Market size and forecast 2019-2024
      • Table Global market: Size and forecast 2019-2024 ($ millions)
      • Table Global market: Year-over-year growth 2020-2024 (%)
  • Five forces analysis
    • Table Five forces analysis 2019
    • Table Five forces analysis 2024
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2019
  • Pipeline analysis
    • Table Late-stage pipeline
  • Market segmentation by type
    • Table Type - Market share 2019-2024 (%)
    • Comparison by type
      • Table Comparison by type
    • Hemophilia A - Market size and forecast 2019-2024
      • Table Hemophilia A - Market size and forecast 2019-2024 ($ millions)
      • Table Hemophilia A - Year-over-year growth 2020-2024 (%)
    • Hemophilia B - Market size and forecast 2019-2024
      • Table Hemophilia B - Market size and forecast 2019-2024 ($ millions)
      • Table Hemophilia B - Year-over-year growth 2020-2024 (%)
    • Von Willebrand disease - Market size and forecast 2019- 2024
      • Table Von Willebrand disease - Market size and forecast 2019-2024 ($ millions)
      • Table Von Willebrand disease - Year-over-year growth 2020-2024 (%)
    • Other disorders - Market size and forecast 2019-2024
      • Table Other disorders - Market size and forecast 2019-2024 ($ millions)
      • Table Other disorders - Year-over-year growth 2020-2024 (%)
    • Market opportunity by type
      • Table Market opportunity by type
  • Customer landscape
    • Table Customer landscape
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2019-2024 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2019-2024
      • Table North America - Market size and forecast 2019-2024 ($ millions)
      • Table North America - Year-over-year growth 2020-2024 (%)
      • Table Top 3 countries in North America
    • Europe - Market size and forecast 2019-2024
      • Table Europe - Market size and forecast 2019-2024 ($ millions)
      • Table Europe - Year-over-year growth 2020-2024 (%)
      • Table Top 3 countries in Europe
    • Asia - Market size and forecast 2019-2024
      • Table Asia - Market size and forecast 2019-2024 ($ millions)
      • Table Asia - Year-over-year growth 2020-2024 (%)
      • Table Top 3 countries in Asia
    • ROW - Market size and forecast 2019-2024
      • Table ROW - Market size and forecast 2019-2024 ($ millions)
      • Table ROW - Year-over-year growth 2020-2024 (%)
      • Table Top 3 countries in ROW
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
      • Table Impact of drivers and challenges
  • Market trends
    • R&D of novel therapies
    • Emergence of gene therapy
    • Advent of bispecific antibodies
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
    • Competitive scenario
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • Baxter International Inc.
      • Table Baxter International Inc. - Vendor overview
      • Table Baxter International Inc. - Business segments
      • Table Baxter International Inc. - Organizational developments
      • Table Baxter International Inc. - Geographic focus
      • Table Baxter International Inc. - Segment focus
      • Table Baxter International Inc. - Key offerings
      • Table Baxter International Inc. - Key customers
    • Bayer AG
      • Table Bayer AG - Vendor overview
      • Table Bayer AG - Business segments
      • Table Bayer AG - Organizational developments
      • Table Bayer AG - Geographic focus
      • Table Bayer AG - Segment focus
      • Table Bayer AG - Key offerings
      • Table Bayer AG - Key customers
    • CSL Ltd.
      • Table CSL Ltd. - Vendor overview
      • Table CSL Ltd. - Business segments
      • Table CSL Ltd. - Organizational developments
      • Table CSL Ltd. - Geographic focus
      • Table CSL Ltd. - Segment focus
      • Table CSL Ltd. - Key offerings
      • Table CSL Ltd. - Key customers
    • F. Hoffmann-La Roche Ltd.
      • Table F. Hoffmann-La Roche Ltd. - Vendor overview
      • Table F. Hoffmann-La Roche Ltd. - Business segments
      • Table F. Hoffmann-La Roche Ltd. - Organizational developments
      • Table F. Hoffmann-La Roche Ltd. - Geographic focus
      • Table F. Hoffmann-La Roche Ltd. - Segment focus
      • Table F. Hoffmann-La Roche Ltd. - Key offerings
      • Table F. Hoffmann-La Roche Ltd. - Key customers
    • Grifols SA
      • Table Grifols SA - Vendor overview
      • Table Grifols SA - Business segments
      • Table Grifols SA - Organizational developments
      • Table Grifols SA - Geographic focus
      • Table Grifols SA - Segment focus
      • Table Grifols SA - Key offerings
      • Table Grifols SA - Key customers
    • Novo Nordisk AS
      • Table Novo Nordisk AS - Vendor overview
      • Table Novo Nordisk AS - Business segments
      • Table Novo Nordisk AS - Organizational developments
      • Table Novo Nordisk AS - Geographic focus
      • Table Novo Nordisk AS - Segment focus
      • Table Novo Nordisk AS - Key offerings
      • Table Novo Nordisk AS - Key customers
    • Octapharma AG
      • Table Octapharma AG - Vendor overview
      • Table Octapharma AG - Organizational developments
      • Table Octapharma AG - Key offerings
      • Table Octapharma AG - Key customers
    • Pfizer Inc.
      • Table Pfizer Inc. - Vendor overview
      • Table Pfizer Inc. - Business segments
      • Table Pfizer Inc. - Organizational developments
      • Table Pfizer Inc. - Geographic focus
      • Table Pfizer Inc. - Segment focus
      • Table Pfizer Inc. - Key offerings
      • Table Pfizer Inc. - Key customers
    • Sanofi
      • Table Sanofi - Vendor overview
      • Table Sanofi - Business segments
      • Table Sanofi - Organizational developments
      • Table Sanofi - Geographic focus
      • Table Sanofi - Segment focus
      • Table Sanofi - Key offerings
      • Table Sanofi - Key customers
    • Takeda Pharmaceutical Co. Ltd.
      • Table Takeda Pharmaceutical Co. Ltd. - Vendor overview
      • Table Takeda Pharmaceutical Co. Ltd. - Business segments
      • Table Takeda Pharmaceutical Co. Ltd. - Organizational developments
      • Table Takeda Pharmaceutical Co. Ltd. - Geographic focus
      • Table Takeda Pharmaceutical Co. Ltd. - Key offerings
      • Table Takeda Pharmaceutical Co. Ltd. - Key customers
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
    • Definition of market positioning of vendors
      • Table Definition of market positioning of vendors
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook